Sotoxen 120 mg (Sotorasib) Tablets


Sotoxen 120 mg (Sotorasib) Tablets


Sotoxen 120 mg, a product of Everest Pharmaceuticals Ltd. and distributed by Orio Pharma, represents a significant breakthrough in precision oncology. This innovative medication, with Sotorasib as its active ingredient, marks a new chapter in the treatment of cancers with specific genetic mutations, particularly those with the KRAS G12C mutation.

Manufacturing Excellence of Everest Pharmaceuticals Ltd.:

Everest Pharmaceuticals Ltd. is renowned for its commitment to innovation and quality in pharmaceutical manufacturing. The development of Sotoxen 120 mg epitomizes their dedication to creating advanced therapies that address unmet needs in cancer treatment.

Mechanism of Action:

Sotoxen 120 mg works by targeting the KRAS G12C mutation, a common genetic alteration in various solid tumors. Sotorasib, the active compound in Sotoxen, selectively inhibits this mutation, effectively blocking the abnormal signaling pathways that contribute to cancer cell growth and proliferation.

Clinical Applications:

Sotoxen 120 mg is primarily indicated for:

  1. Treatment of Solid Tumors with KRAS G12C Mutation: It offers a promising treatment option for patients with advanced solid tumors harboring this specific mutation, a subset of cancer that has historically been challenging to treat effectively.

Dosage and Administration:

The prescribed dosage of Sotoxen 120 mg is determined based on the patient’s medical condition and response to treatment. Taken orally, this medication provides a convenient treatment regimen, enhancing patient compliance and treatment efficacy. Regular monitoring by healthcare professionals is essential to optimize the therapeutic outcomes and adjust the treatment as necessary.

Benefits of Sotoxen 120 mg:

  1. Precision Targeting: Sotoxen 120 mg’s ability to specifically target KRAS G12C mutations offers a tailored and more effective treatment approach, reducing the impact on healthy cells compared to traditional chemotherapy.
  2. Historical Breakthrough: The development of Sotoxen 120 mg represents a significant advancement in treating cancers with KRAS mutations, providing new hope for patients who previously had limited treatment options.
  3. Improved Quality of Life: By effectively targeting the genetic drivers of cancer, Sotoxen 120 mg can improve patients’ quality of life, managing symptoms more effectively and allowing for better overall well-being during treatment.

Distribution by Orio Pharma:

Orio Pharma plays a crucial role in the distribution of Sotoxen 120 mg, ensuring that this innovative treatment is accessible to healthcare providers and patients worldwide. Their commitment to supply chain excellence guarantees that Sotoxen 120 mg is available where and when it’s needed most.


Sotoxen 120 mg (Sotorasib) is more than just a medication; it is a symbol of hope and progress in the fight against cancer. The collaboration between Everest Pharmaceuticals Ltd. and Orio Pharma is instrumental in bringing this advanced therapy to patients, contributing significantly to the ongoing battle against KRAS G12C-mutated tumors. This partnership exemplifies the collaborative spirit driving medical advancements, offering renewed hope to patients and families affected by these challenging conditions.